Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 78
- Registration Number
- NCT06582628
- Locations
- 🇪🇸
Institut Català d'Oncologia (ICO), Badalona, Barcelona, Spain
🇪🇸Consorcio Corporación Sanitaria Parc TaulÃ, Sabadell, Barcelona, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 18
- Registration Number
- NCT06377722
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario de Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 42
- Registration Number
- NCT05563558
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 24
- Registration Number
- NCT04494958
- Locations
- 🇪🇸
Hospital QuirónSalud Madrid, Madrid, Spain
🇪🇸Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 184
- Registration Number
- NCT04253145
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Cataluña, Spain
🇪🇸Hospital Universitario Da Coruña, A Coruña, Spain
🇪🇸Hospital Virgen del Rocio, Sevilla, Andalucia, Spain
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 40
- Registration Number
- NCT04134000
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 60
- Registration Number
- NCT01763710
- Locations
- 🇪🇸
Hospital Universitario Del Sureste, Arganda del Rey, Madrid, Spain
🇪🇸Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸Hospital Universitario Infanta Leonor, Madrid, Spain